On August 25, 2025, BeOne Medicines Ltd. announced a $885 million Royalty Purchase Agreement with Royalty Pharma, allowing Royalty Pharma to receive tiered royalty payments based on mid-single digit percentages of sales of their monoclonal antibody Imdelltra outside of China. This agreement also includes an option for an additional $65 million in royalties and retains the company's other rights under a collaboration with Amgen.